Antiarrhythmic therapy in atrial fibrillation

Pharmacology and Therapeutics

Volumn 128, Issue 1, 2010, Pages 129-145

  Ravens, Ursula ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Atrial fibrillation; Atrial ion channels; Atrial selective drugs; Constitutively active IK,ACh; Electrical remodelling; IKur blockers

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; 2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; 2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; 2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIARRHYTHMIC PEPTIDE; AVE 1231; AZIMILIDE; DIPHENYLPHOSPHINE OXIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; GAP 134; IBUTILIDE; NIFEKALANT; NIP 142; NIP 151; PROPAFENONE; RANOLAZINE; ROTIGAPTIDE; S 20951; S 9947; SOTALOL; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT;

ANTIARRHYTHMIC ACTIVITY; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DEFIBRILLATOR; DRUG MECHANISM; DRUG TARGETING; GAP JUNCTION; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM PACING; HEART BLOCK; HEART EXCITATION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART RATE; HEART REPOLARIZATION; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QT PROLONGATION; REENTRY ARRHYTHMIA; REVIEW; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; GAP JUNCTIONS; HEART ATRIA; HUMANS; ION CHANNELS;

EID: 79951872503     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.06.004     Document Type: Review

References (259)

1. The Sicilian Gambit A New Approach to the Classification of Antiarrhythmic Drugs Based on Their Actions on Arrhythmogenic Mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 1991, 84:1831-1851.
2. Aiello E.A., Cingolani H.E. Angiotensin II Stimulates Cardiac L-Type Ca(2+) Current by a Ca(2+)- and Protein Kinase C-Dependent Mechanism. Am J Physiol Heart Circ Physiol 2001, 280:H1528-H1536.
3. Aksnes T.A., Flaa A., Strand A., Kjeldsen S.E. Prevention of New-Onset Atrial Fibrillation and Its Predictors With Angiotensin II-Receptor Blockers in the Treatment of Hypertension and Heart Failure. J Hypertens 2007, 25:15-23.
4. Alboni P., Botto G.L., Baldi N., Luzi M., Russo V., Gianfranchi L., et al. Outpatient Treatment of Recent-Onset Atrial Fibrillation With the "Pill-in-the-Pocket" Approach. N Engl J Med 2004, 351:2384-2391.
5. Allessie M.A., Bonke F.I., Schopman F.J. Circus Movement in Rabbit Atrial Muscle As a Mechanism of Tachycardia. III. The "Leading Circle" Concept: a New Model of Circus Movement in Cardiac Tissue Without the Involvement of an Anatomical Obstacle. Circ Res 1977, 41:9-18.
6. Amos G.J., Wettwer E., Metzger F., Li Q., Himmel H.M., Ravens U. Differences Between Outward Currents of Human Atrial and Subepicardial Ventricular Myocytes. J Physiol 1996, 491(Pt 1):31-50.
7. Antzelevitch C., Belardinelli L., Zygmunt A.C., Burashnikov A., Di Diego J.M., Fish J.M., et al. Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties. Circulation 2004, 110:904-910.
8. Antzelevitch C., Burashnikov A. Atrial-Selective Sodium Channel Block As a Novel Strategy for the Management of Atrial Fibrillation. J Electrocardiol 2009, 42:543-548.
9. Aonuma S., Kohama Y., Akai K., Komiyama Y., Nakajima S., Wakabayashi M., et al. Studies on Heart. XIX. Isolation of an Atrial Peptide That Improves the Rhythmicity of Cultured Myocardial Cell Clusters. Chem Pharm Bull (Tokyo) 1980, 28:3332-3339.
10. Ausma J., van der Velden H.M., Lenders M.H., van Ankeren E.P., Jongsma H.J., Ramaekers F.C., et al. Reverse Structural and Gap-Junctional Remodeling After Prolonged Atrial Fibrillation in the Goat. Circulation 2003, 107:2051-2058.
11. Ausma J., Wijffels M., Thone F., Wouters L., Allessie M., Borgers M. Structural Changes of Atrial Myocardium Due to Sustained Atrial Fibrillation in the Goat. Circulation 1997, 96:3157-3163.
12. Bachmann A., Gutcher I., Kopp K., Brendel J., Bosch R.F., Busch A.E., et al. Characterization of a Novel Kv1.5 Channel Blocker in Xenopus Oocytes, CHO Cells, Human and Rat Cardiomyocytes 1. Naunyn Schmiedebergs Arch Pharmacol 2001, 364:472-478.
13. Bachmann J.M., Majmudar M., Tompkins C., Blumenthal R.S., Marine J.E. Lipid-Altering Therapy and Atrial Fibrillation. Cardiol Rev 2008, 16:197-204.
14. Baskin E.P., Lynch J.J. Differential Atrial Versus Ventricular Activities of Class III Potassium Channel Blockers. J Pharmacol Exp Ther 1998, 285:135-142.
15. Benjamin E.J., Chen P.S., Bild D.E., Mascette A.M., Albert C.M., Alonso A., et al. Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop. Circulation 2009, 119:606-618.
16. Berenfeld O., Zaitsev A.V., Mironov S.F., Pertsov A.M., Jalife J. Frequency-Dependent Breakdown of Wave Propagation into Fibrillatory Conduction Across the Pectinate Muscle Network in the Isolated Sheep Right Atrium. Circ Res 2002, 90:1173-1180.
17. Bers D.M. Cardiac Excitation-Contraction Coupling. Nature 2002, 415:198-205.
18. Birinyi P., Acsai K., Banyasz T., Toth A., Horvath B., Virag L., et al. Effects of SEA0400 and KB-R7943 on Na+/Ca2+ Exchange Current and L-Type Ca2+ Current in Canine Ventricular Cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 2005, 372:63-70.
19. Blaauw Y., Gogelein H., Tieleman R.G., van Hunnik A., Schotten U., Allessie M.A. "Early" Class III Drugs for the Treatment of Atrial Fibrillation: Efficacy and Atrial Selectivity of AVE0118 in Remodeled Atria of the Goat. Circulation 2004, 110:1717-1724.
20. Bode F., Sachs F., Franz M.R. Tarantula Peptide Inhibits Atrial Fibrillation. Nature 2001, 409:35-36.
21. Boland L.M., Drzewiecki M.M. Polyunsaturated Fatty Acid Modulation of Voltage-Gated Ion Channels. Cell Biochem Biophys 2008, 52:59-84.
22. Boland L.M., Drzewiecki M.M., Timoney G., Casey E. Inhibitory Effects of Polyunsaturated Fatty Acids on Kv4/KChIP Potassium Channels. Am J Physiol Cell Physiol 2009, 296:C1003-C1014.
23. Bosch R.F., Nattel S. Cellular Electrophysiology of Atrial Fibrillation. Cardiovasc Res 2002, 54:259-269.
24. Bosch R.F., Scherer C.R., Rub N., Wohrl S., Steinmeyer K., Haase H., et al. Molecular Mechanisms of Early Electrical Remodeling: Transcriptional Downregulation of Ion Channel Subunits Reduces I(Ca, L) and I(to) in Rapid Atrial Pacing in Rabbits. J Am Coll Cardiol 2003, 41:858-869.
25. Bosch R.F., Zeng X., Grammer J.B., Popovic K., Mewis C., Kuhlkamp V. Ionic Mechanisms of Electrical Remodeling in Human Atrial Fibrillation. Cardiovasc Res 1999, 44:121-131.
26. Brendorp B., Pedersen O., Torp-Pedersen C., Sahebzadah N., Kober L. A Benefit-Risk Assessment of Class III Antiarrhythmic Agents. Drug Saf 2002, 25:847-865.
27. + Channels. J Am Coll Cardiol 2001, 37:926-932.
28. Burashnikov A., Antzelevitch C. New Developments in Atrial Antiarrhythmic Drug Therapy. Nat Rev Cardiol 2010, 7:139-148.
29. Burashnikov A., Di Diego J.M., Zygmunt A.C., Belardinelli L., Antzelevitch C. Atrium-Selective Sodium Channel Block As a Strategy for Suppression of Atrial Fibrillation: Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine. Circulation 2007, 116:1449-1457.
30. Burstein B., Nattel S. Atrial Structural Remodeling As an Antiarrhythmic Target. J Cardiovasc Pharmacol 2008, 52:4-10.
31. Butera J.A., Larsen B.D., Hennan J.K., Kerns E., Di L., Alimardanov A., et al. Discovery of (2S, 4R)-1-(2-Aminoacetyl)-4-Benzamidopyrrolidine-2-Carboxylic Acid Hydrochloride (GAP-134)13, an Orally Active Small Molecule Gap-Junction Modifier for the Treatment of Atrial Fibrillation. J Med Chem 2009, 52:908-911.
32. Carlsson L., Chartier D., Nattel S. Characterization of the In Vivo and In Vitro Electrophysiological Effects of the Novel Antiarrhythmic Agent AZD7009 in Atrial and Ventricular Tissue of the Dog. J Cardiovasc Pharmacol 2006, 47:123-132.
33. Carmeliet E. Voltage- and Time-Dependent Block of the Delayed K+Current in Cardiac Myocytes by Dofetilide. J Pharmacol Exp Ther 1992, 262:809-817.
34. Carnes C.A., Chung M.K., Nakayama T., Nakayama H., Baliga R.S., Piao S., et al. Ascorbate Attenuates Atrial Pacing-Induced Peroxynitrite Formation and Electrical Remodeling and Decreases the Incidence of Postoperative Atrial Fibrillation. Circ Res 2001, 89:E32-E38.
35. Cha T.J., Ehrlich J.R., Chartier D., Qi X.Y., Xiao L., Nattel S. Kir3-Based Inward Rectifier Potassium Current: Potential Role in Atrial Tachycardia Remodeling Effects on Atrial Repolarization and Arrhythmias. Circulation 2006, 113:1730-1737.
36. Charlier R., Deltour G., Baudine A., Chaillet F. Pharmacology of Amiodarone, and Anti-Anginal Drug With a New Biological Profile. Arzneimittelforschung 1968, 18:1408-1417.
37. Chatelain P., Meysmans L., Matteazzi J.R., Beaufort P., Clinet M. Interaction of the Antiarrhythmic Agents SR 33589 and Amiodarone With the Beta-Adrenoceptor and Adenylate Cyclase in Rat Heart. Br J Pharmacol 1995, 116:1949-1956.
38. Chen Y.J., Chen S.A., Tai C.T., Wen Z.C., Feng A.N., Ding Y.A., et al. Role of Atrial Electrophysiology and Autonomic Nervous System in Patients With Supraventricular Tachycardia and Paroxysmal Atrial Fibrillation. J Am Coll Cardiol 1998, 32:732-738.
39. 2+ Current Downregulation in Chronic Human Atrial Fibrillation Is Associated With Increased Activity of Protein Phosphatases. Circulation 2004, 110:2651-2657.
40. Christ T., Wettwer E., Voigt N., Hala O., Radicke S., Matschke K., et al. Pathology-Specific Effects of the I(Kur)/I(to)/I(K, ACh) Blocker AVE0118 on Ion Channels in Human Chronic Atrial Fibrillation. Br J Pharmacol 2008, 154:1619-1630.
41. Clark R.B., Nakajima T., Giles W., Kanai K., Momose Y., Szabo G. Two Distinct Types of Inwardly Rectifying K+Channels in Bull-Frog Atrial Myocytes. J Physiol 1990, 424:229-251.
42. Clarke T.C., Thomas D., Petersen J.S., Evans W.H., Martin P.E. The Antiarrhythmic Peptide Rotigaptide (ZP123) Increases Gap Junction Intercellular Communication in Cardiac Myocytes and HeLa Cells Expressing Connexin 43. Br J Pharmacol 2006, 147:486-495.
43. Comtois P., Kneller J., Nattel S. Of Circles and Spirals: Bridging the Gap Between the Leading Circle and Spiral Wave Concepts of Cardiac Reentry. Europace 2005, 7(Suppl 2):10-20.
44. Crijns H.J., van Gelder I.C., Walfridsson H., Kulakowski P., Ronaszeki A., Dedek V., et al. Safe and Effective Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009. Heart Rhythm 2006, 3:1321-1331.
45. Davignon J. Beneficial Cardiovascular Pleiotropic Effects of Statins. Circulation 2004, 109:III39-III43.
46. Dawe D.E., Ariyarajah V., Khadem A. Is There a Role for Statins in Atrial Fibrillation?. Pacing Clin Electrophysiol 2009, 32:1063-1072.
47. to) and Ultrarapid Delayed Rectifier Current (IKur), Fully Restores Atrial Contractility After Cardioversion of Atrial Fibrillation in the Goat. Circulation 2006, 114:1234-1242.
48. Decher N., Kumar P., Gonzalez T., Pirard B., Sanguinetti M.C. Binding Site of a Novel Kv1.5 Blocker: a "Foot in the Door" Against Atrial Fibrillation. Mol Pharmacol 2006, 70:1204-1211.
49. Delacretaz E. Clinical Practice. Supraventricular Tachycardia. N Engl J Med 2006, 354:1039-1051.
50. Dhein S., Hagen A., Jozwiak J., Dietze A., Garbade J., Barten M., et al. Improving Cardiac Gap Junction Communication As a New Antiarrhythmic Mechanism: the Action of Antiarrhythmic Peptides. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:221-234.
51. Dhein S., Manicone N., Muller A., Gerwin R., Ziskoven U., Irankhahi A., et al. A New Synthetic Antiarrhythmic Peptide Reduces Dispersion of Epicardial Activation Recovery Interval and Diminishes Alterations of Epicardial Activation Patterns Induced by Regional Ischemia. A Mapping Study. Naunyn Schmiedebergs Arch Pharmacol 1994, 350:174-184.
52. Disertori M., Latini R., Barlera S., Franzosi M.G., Staszewsky L., Maggioni A.P., et al. Valsartan for Prevention of Recurrent Atrial Fibrillation. N Engl J Med 2009, 360:1606-1617.
53. Dobrev D. Atrial Ca2+ Signaling in Atrial Fibrillation As an Antiarrhythmic Drug Target. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:195-206.
54. Dobrev D., Friedrich A., Voigt N., Jost N., Wettwer E., Christ T., et al. The G Protein-Gated Potassium Current I(K, ACh) Is Constitutively Active in Patients With Chronic Atrial Fibrillation. Circulation 2005, 112:3697-3706.
55. Dobrev D., Graf E., Wettwer E., Himmel H.M., Hala O., Doerfel C., et al. Molecular Basis of Downregulation of G-Protein-Coupled Inward Rectifying K+Current (IK, ACh) in Chronic Human Atrial Fibrillation: Decrease in GIRK4 MRNA Correlates With Reduced I(K, ACh) and Muscarinic Receptor-Mediated Shortening of Action Potentials. Circulation 2001, 104:2551-2557.
56. Dobrev D., Nattel S. Calcium Handling Abnormalities in Atrial Fibrillation As a Target for Innovative Therapeutics. J Cardiovasc Pharmacol 2008, 52:293-299.
57. Dobrev D., Ravens U. Remodeling of Cardiomyocyte Ion Channels in Human Atrial Fibrillation. Basic Res Cardiol 2003, 98:137-148.
58. Dobrzynski H., Marples D.D., Musa H., Yamanushi T.T., Henderson Z., Takagishi Y., et al. Distribution of the Muscarinic K+Channel Proteins Kir3.1 and Kir3.4 in the Ventricle, Atrium, and Sinoatrial Node of Heart. J Histochem Cytochem 2001, 49:1221-1234.
59. Duffy H.S., Wit A.L. Is There a Role for Remodeled Connexins in AF? No Simple Answers. J Mol Cell Cardiol 2008, 44:4-13.
60. Dukes I.D., Cleemann L., Morad M. Tedisamil Blocks the Transient and Delayed Rectifier K+Currents in Mammalian Cardiac and Glial Cells. J Pharmacol Exp Ther 1990, 254:560-569.
61. Dukes I.D., Morad M. Tedisamil Inactivates Transient Outward K+Current in Rat Ventricular Myocytes. Am J Physiol 1989, 257:H1746-H1749.
62. Dyachenko V., Husse B., Rueckschloss U., Isenberg G. Mechanical Deformation of Ventricular Myocytes Modulates Both TRPC6 and Kir2.3 Channels. Cell Calcium 2009, 45:38-54.
63. Easton J.A., Petersen J.S., Martin P.E. The Anti-Arrhythmic Peptide AAP10 Remodels Cx43 and Cx40 Expression and Function. Naunyn Schmiedebergs Arch Pharmacol 2009, 380:11-24.
64. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., et al. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781-788.
65. Ehrlich J.R., Cha T.J., Zhang L., Chartier D., Villeneuve L., Hebert T.E., et al. Characterization of a Hyperpolarization-Activated Time-Dependent Potassium Current in Canine Cardiomyocytes From Pulmonary Vein Myocardial Sleeves and Left Atrium. J Physiol 2004, 557:583-597.
66. El Armouche A., Boknik P., Eschenhagen T., Carrier L., Knaut M., Ravens U., et al. Molecular Determinants of Altered Ca2+ Handling in Human Chronic Atrial Fibrillation. Circulation 2006, 114:670-680.
67. Ellinor P.T., Lunetta K.L., Glazer N.L., Pfeufer A., Alonso A., Chung M.K., et al. Common Variants in KCNN3 Are Associated With Lone Atrial Fibrillation. Nat Genet 2010, 42:240-244.
68. Ellinor P.T., Nam E.G., Shea M.A., Milan D.J., Ruskin J.N., Macrae C.A. Cardiac Sodium Channel Mutation in Atrial Fibrillation. Heart Rhythm 2008, 5:99-105.
69. Fedida D. Vernakalant (RSD1235): a Novel, Atrial-Selective Antifibrillatory Agent. Expert Opin Investig Drugs 2007, 16:519-532.
70. Fedida D., Eldstrom J., Hesketh J.C., Lamorgese M., Castel L., Steele D.F., et al. Kv1.5 Is an Important Component of Repolarizing K+Current in Canine Atrial Myocytes. Circ Res 2003, 93:744-751.
71. Fedida D., Orth P.M., Chen J.Y., Lin S., Plouvier B., Jung G., et al. The Mechanism of Atrial Antiarrhythmic Action of RSD1235. J Cardiovasc Electrophysiol 2005, 16:1227-1238.
72. Fischbach P.S., Johnston P.V., Friedrichs G.S., Lucchesi B.R. Tedisamil in a Chronic Canine Model of Atrial Flutter. J Cardiovasc Pharmacol 1999, 34:212-218.
73. Ford J.W., Milnes J.T. New Drugs Targeting the Cardiac Ultra-Rapid Delayed-Rectifier Current (I Kur): Rationale, Pharmacology and Evidence for Potential Therapeutic Value. J Cardiovasc Pharmacol 2008, 52:105-120.
74. Fox C.S., Parise H., D'Agostino R.B., Lloyd-Jones D.M., Vasan R.S., Wang T.J., et al. Parental Atrial Fibrillation As a Risk Factor for Atrial Fibrillation in Offspring. JAMA 2004, 291:2851-2855.
75. Fragakis N., Bikias A., Delithanasis I., Konstantinidou M., Liakopoulos N., Kozirakis M., et al. Acute Beta-Adrenoceptor Blockade Improves Efficacy of Ibutilide in Conversion of Atrial Fibrillation With a Rapid Ventricular Rate. Europace 2009, 11:70-74.
76. Freedberg A.S., Papp J.G., Williams E.M. The Effect of Altered Thyroid State on Atrial Intracellular Potentials. J Physiol 1970, 207:357-369.
77. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2006, 27:1979-2030.
78. Gaborit N., Steenman M., Lamirault G., Le Meur N., Le Bouter S., Lande G., et al. Human Atrial Ion Channel and Transporter Subunit Gene-Expression Remodeling Associated With Valvular Heart Disease and Atrial Fibrillation. Circulation 2005, 112:471-481.
79. Gaspo R., Bosch R.F., Bou-Abboud E., Nattel S. Tachycardia-Induced Changes in Na+Current in a Chronic Dog Model of Atrial Fibrillation. Circ Res 1997, 81:1045-1052.
80. Gautier P., Guillemare E., Marion A., Bertrand J.P., Tourneur Y., Nisato D. Electrophysiologic Characterization of Dronedarone in Guinea Pig Ventricular Cells. J Cardiovasc Pharmacol 2003, 41:191-202.
81. Geller J.C., Egstrup K., Kulakowski P., Rosenqvist M., Jansson M.A., Berggren A., et al. Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009. J Clin Pharmacol 2009, 49:312-322.
82. Gierten J., Ficker E., Bloehs R., Schlomer K., Kathofer S., Scholz E., et al. Regulation of Two-Pore-Domain (K2P) Potassium Leak Channels by the Tyrosine Kinase Inhibitor Genistein. Br J Pharmacol 2008, 154:1680-1690.
83. Gierten J., Ficker E., Bloehs R., Schweizer P.A., Zitron E., Scholz E., et al. The Human Cardiac K2P3.1 (TASK-1) Potassium Leak Channel Is a Molecular Target for the Class III Antiarrhythmic Drug Amiodarone. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:261-270.
84. Goette A., Bukowska A., Lendeckel U. Non-Ion Channel Blockers As Anti-Arrhythmic Drugs (Reversal of Structural Remodeling). Curr Opin Pharmacol 2007, 7:219-224.
85. Goette A., Lendeckel U. Nonchannel Drug Targets in Atrial Fibrillation. Pharmacol Ther 2004, 102:17-36.
86. Gogelein H., Brendel J., Steinmeyer K., Strubing C., Picard N., Rampe D., et al. Effects of the Atrial Antiarrhythmic Drug AVE0118 on Cardiac Ion Channels. Naunyn Schmiedebergs Arch Pharmacol 2004, 370:183-192.
87. Goldstein R.N., Khrestian C., Carlsson L., Waldo A.L. Azd7009: a New Antiarrhythmic Drug With Predominant Effects on the Atria Effectively Terminates and Prevents Reinduction of Atrial Fibrillation and Flutter in the Sterile Pericarditis Model. J Cardiovasc Electrophysiol 2004, 15:1444-1450.
88. Goldstein S.A., Bockenhauer D., O'Kelly I., Zilberberg N. Potassium Leak Channels and the KCNK Family of Two-P-Domain Subunits. Nat Rev Neurosci 2001, 2:175-184.
89. Guerra J.M., Everett T.H., Lee K.W., Wilson E., Olgin J.E. Effects of the Gap Junction Modifier Rotigaptide (ZP123) on Atrial Conduction and Vulnerability to Atrial Fibrillation. Circulation 2006, 114:110-118.
90. Guillemare E., Marion A., Nisato D., Gautier P. Inhibitory Effects of Dronedarone on Muscarinic K+Current in Guinea Pig Atrial Cells. J Cardiovasc Pharmacol 2000, 36:802-805.
91. Guinamard R., Chatelier A., Demion M., Potreau D., Patri S., Rahmati M., et al. Functional Characterization of a Ca(2+)-Activated Non-Selective Cation Channel in Human Atrial Cardiomyocytes. J Physiol 2004, 558:75-83.
92. Guinamard R., Demion M., Chatelier A., Bois P. Calcium-Activated Nonselective Cation Channels in Mammalian Cardiomyocytes. Trends Cardiovasc Med 2006, 16:245-250.
93. Haissaguerre M., Jais P., Shah D.C., Garrigue S., Takahashi A., Lavergne T., et al. Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Pulmonary Venous Foci. Circulation 2000, 101:1409-1417.
94. Haissaguerre M., Jais P., Shah D.C., Takahashi A., Hocini M., Quiniou G., et al. Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins. N Engl J Med 1998, 339:659-666.
95. Hartzell H.C. Regulation of Cardiac Ion Channels by Catecholamines, Acetylcholine and Second Messenger Systems. Prog Biophys Mol Biol 1988, 52:165-247.
96. Hashimoto N., Yamashita T., Tsuruzoe N. Tertiapin, a Selective IKACh Blocker, Terminates Atrial Fibrillation With Selective Atrial Effective Refractory Period Prolongation. Pharmacol Res 2006, 54:136-141.
97. Hashimoto N., Yamashita T., Tsuruzoe N. Characterization of in Vivo and in Vitro Electrophysiological and Antiarrhythmic Effects of a Novel IKACh Blocker, NIP-151: a Comparison With an IKr-Blocker Dofetilide. J Cardiovasc Pharmacol 2008, 51:162-169.
98. Haugan K., Lam H.R., Knudsen C.B., Petersen J.S. Atrial Fibrillation in Rats Induced by Rapid Transesophageal Atrial Pacing During Brief Episodes of Asphyxia: a New in Vivo Model. J Cardiovasc Pharmacol 2004, 44:125-135.
99. Haugan K., Olsen K.B., Hartvig L., Petersen J.S., Holstein-Rathlou N.H., Hennan J.K., et al. The Antiarrhythmic Peptide Analog ZP123 Prevents Atrial Conduction Slowing During Metabolic Stress. J Cardiovasc Electrophysiol 2005, 16:537-545.
100. Heeringa J., van der Kuip D.A., Hofman A., Kors J.A., van Herpen G., Stricker B.H., et al. Prevalence, Incidence and Lifetime Risk of Atrial Fibrillation: the Rotterdam Study. Eur Heart J 2006, 27:949-953.
101. Hoffmann E., Sulke N., Edvardsson N., Ruiter J., Lewalter T., Capucci A., et al. New Insights into the Initiation of Atrial Fibrillation: a Detailed Intraindividual and Interindividual Analysis of the Spontaneous Onset of Atrial Fibrillation Using New Diagnostic Pacemaker Features. Circulation 2006, 113:1933-1941.
102. Hohnloser S.H., Dorian P., Straub M., Beckmann K., Kowey P. Safety and Efficacy of Intravenously Administered Tedisamil for Rapid Conversion of Recent-Onset Atrial Fibrillation or Atrial Flutter. J Am Coll Cardiol 2004, 44:99-104.
103. Hondeghem L.M., Katzung B.G. Antiarrhythmic Agents: the Modulated Receptor Mechanism of Action of Sodium and Calcium Channel-Blocking Drugs. Annu Rev Pharmacol Toxicol 1984, 24:387-423.
104. Hove-Madsen L., Llach A., Bayes-Genis A., Roura S., Rodriguez F.E., Aris A., et al. Atrial Fibrillation Is Associated With Increased Spontaneous Calcium Release From the Sarcoplasmic Reticulum in Human Atrial Myocytes. Circulation 2004, 110:1358-1363.
105. Inagaki K., Kihara Y., Hayashida W., Izumi T., Iwanaga Y., Yoneda T., et al. Anti-Ischemic Effect of a Novel Cardioprotective Agent, JTV519, Is Mediated Through Specific Activation of Delta-Isoform of Protein Kinase C in Rat Ventricular Myocardium. Circulation 2000, 101:797-804.
106. Iwamoto T., Watanabe Y., Kita S., Blaustein M.P. Na+/Ca2+ Exchange Inhibitors: a New Class of Calcium Regulators. Cardiovasc Hematol Disord Drug Targets 2007, 7:188-198.
107. Jahnel U., Rupp J., Ertl R., Nawrath H. Positive Inotropic Response to 5-HT in Human Atrial but Not in Ventricular Heart Muscle. Naunyn Schmiedebergs Arch Pharmacol 1992, 346:482-485.
108. Jalife J. Ventricular Fibrillation: Mechanisms of Initiation and Maintenance. Annu Rev Physiol 2000, 62:25-50.
109. Jibrini M.B., Molnar J., Arora R.R. Prevention of Atrial Fibrillation by Way of Abrogation of the Renin-Angiotensin System: a Systematic Review and Meta-Analysis. Am J Ther 2008, 15:36-43.
110. Jozwiak J., Dhein S. Local Effects and Mechanisms of Antiarrhythmic Peptide AAP10 in Acute Regional Myocardial Ischemia: Electrophysiological and Molecular Findings. Naunyn Schmiedebergs Arch Pharmacol 2008, 378:459-470.
111. Kaibara M., Nakajima T., Irisawa H., Giles W. Regulation of Spontaneous Opening of Muscarinic K+Channels in Rabbit Atrium. J Physiol 1991, 433:589-613.
112. Kaneko N. 1, 4-Benzothiazepine Derivative, K201, Demonstrates Cardioprotective Effects Against Sudden Cardiac Cell Death and Intracellular Calcium Blocking Action. Drug Dev Res 1994, 33:429-438.
113. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, Incidence, Prognosis, and Predisposing Conditions for Atrial Fibrillation: Population-Based Estimates. Am J Cardiol 1998, 82:2N-9N.
114. Kaufmann R., Theophile U. Autonomously Promoted Extension Effect in Purkinje Fibers, Papillary Muscles and Trabeculae Carneae of Rhesus Monkeys. Pflugers Arch Gesamte Physiol Menschen Tiere 1967, 297:174-189.
115. Kaumann A.J. Do Human Atrial 5-HT4 Receptors Mediate Arrhythmias?. Trends Pharmacol Sci 1994, 15:451-455.
116. Kerr C.R., Connolly S.J., Kowey P., Page R.L., Pritchett E.L., Ruda M.Y., et al. Efficacy of Azimilide for the Maintenance of Sinus Rhythm in Patients With Paroxysmal Atrial Fibrillation in the Presence and Absence of Structural Heart Disease. Am J Cardiol 2006, 98:215-218.
117. Kimura J., Kawahara M., Sakai E., Yatabe J., Nakanishi H. Effects of a Novel Cardioprotective Drug, JTV-519, on Membrane Currents of Guinea Pig Ventricular Myocytes. Jpn J Pharmacol 1999, 79:275-281.
118. Kirchhof P., Bax J., Blomstrom-Lundquist C., Calkins H., Camm A.J., Cappato R., et al. Early and Comprehensive Management of Atrial Fibrillation: Executive Summary of the Proceedings From the 2nd AFNET-EHRA Consensus Conference 'Research Perspectives in AF'. Eur Heart J 2009, 30:2969-2980.
119. Kiriyama K., Kiyosue T., Wang J.C., Dohi K., Arita M. Effects of JTV-519, a Novel Anti-Ischaemic Drug, on the Delayed Rectifier K+Current in Guinea-Pig Ventricular Myocytes. Naunyn Schmiedebergs Arch Pharmacol 2000, 361:646-653.
120. Kjolbye A.L., Dikshteyn M., Eloff B.C., Deschenes I., Rosenbaum D.S. Maintenance of Intercellular Coupling by the Antiarrhythmic Peptide Rotigaptide Suppresses Arrhythmogenic Discordant Alternans. Am J Physiol Heart Circ Physiol 2008, 294:H41-H49.
121. Kjolbye A.L., Knudsen C.B., Jepsen T., Larsen B.D., Petersen J.S. Pharmacological Characterization of the New Stable Antiarrhythmic Peptide Analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in Vivo and in Vitro Studies. J Pharmacol Exp Ther 2003, 306:1191-1199.
122. Knobloch K., Brendel J., Peukert S., Rosenstein B., Busch A.E., Wirth K.J. Electrophysiological and Antiarrhythmic Effects of the Novel I(Kur) Channel Blockers, S9947 and S20951, on Left Vs. Right Pig Atrium in Vivo in Comparison With the I(Kr) Blockers Dofetilide, Azimilide, D,l-Sotalol and Ibutilide. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:482-487.
123. Knobloch K., Brendel J., Rosenstein B., Bleich M., Busch A.E., Wirth K.J. Atrial-Selective Antiarrhythmic Actions of Novel Ikur Vs. Ikr, Iks, and IKAch Class Ic Drugs and Beta Blockers in Pigs. Med Sci Monit 2004, 10:BR221-BR228.
124. Kodama I., Kamiya K., Toyama J. Cellular Electropharmacology of Amiodarone. Cardiovasc Res 1997, 35:13-29.
125. Korantzopoulos P., Kolettis T.M., Galaris D., Goudevenos J.A. The Role of Oxidative Stress in the Pathogenesis and Perpetuation of Atrial Fibrillation. Int J Cardiol 2007, 115:135-143.
126. Kostapanos M.S., Liberopoulos E.N., Goudevenos J.A., Mikhailidis D.P., Elisaf M.S. Do Statins Have an Antiarrhythmic Activity?. Cardiovasc Res 2007, 75:10-20.
127. Koster O.F., Szigeti G.P., Beuckelmann D.J. Characterization of a [Ca2+]i-Dependent Current in Human Atrial and Ventricular Cardiomyocytes in the Absence of Na+and K+. Cardiovasc Res 1999, 41:175-187.
128. Kostin S., Klein G., Szalay Z., Hein S., Bauer E.P., Schaper J. Structural Correlate of Atrial Fibrillation in Human Patients. Cardiovasc Res 2002, 54:361-379.
129. Kourliouros A., Savelieva I., Kiotsekoglou A., Jahangiri M., Camm J. Current Concepts in the Pathogenesis of Atrial Fibrillation. Am Heart J 2009, 157:243-252.
130. Kovoor P., Wickman K., Maguire C.T., Pu W., Gehrmann J., Berul C.I., et al. Evaluation of the Role of I(KACh) in Atrial Fibrillation Using a Mouse Knockout Model. J Am Coll Cardiol 2001, 37:2136-2143.
131. Kozlowski D., Budrejko S., Lip G.Y., Mikhailidis D.P., Rysz J., Raczak G., et al. Vernakalant Hydrochloride for the Treatment of Atrial Fibrillation. Expert Opin Investig Drugs 2009, 18:1929-1937.
132. Kuhlkamp V., Schirdewan A., Stangl K., Homberg M., Ploch M., Beck O.A. Use of Metoprolol CR/XL to Maintain Sinus Rhythm After Conversion From Persistent Atrial Fibrillation: a Randomized, Double-Blind, Placebo-Controlled Study. J Am Coll Cardiol 2000, 36:139-146.
133. Kumagai K., Nakashima H., Gondo N., Saku K. Antiarrhythmic Effects of JTV-519, a Novel Cardioprotective Drug, on Atrial Fibrillation/Flutter in a Canine Sterile Pericarditis Model. J Cardiovasc Electrophysiol 2003, 14:880-884.
134. Kumar K., Nearing B.D., Carvas M., Nascimento B.C., Acar M., Belardinelli L., et al. Ranolazine Exerts Potent Effects on Atrial Electrical Properties and Abbreviates Atrial Fibrillation Duration in the Intact Porcine Heart. J Cardiovasc Electrophysiol 2009, 20:796-802.
135. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., Mahe I., Bergmann J.F. Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: a Systematic Review of Randomized Controlled Trials. Arch Intern Med 2006, 166:719-728.
136. Lagrutta A., Wang J., Fermini B., Salata J.J. Novel, Potent Inhibitors of Human Kv1.5K+Channels and Ultrarapidly Activating Delayed Rectifier Potassium Current. J Pharmacol Exp Ther 2006, 317:1054-1063.
137. Lalevee N., Nargeot J., Barrere-Lemaire S., Gautier P., Richard S. Effects of Amiodarone and Dronedarone on Voltage-Dependent Sodium Current in Human Cardiomyocytes. J Cardiovasc Electrophysiol 2003, 14:885-890.
138. Lampe P.D., Lau A.F. The Effects of Connexin Phosphorylation on Gap Junctional Communication. Int J Biochem Cell Biol 2004, 36:1171-1186.
139. Laurent G., Leong-Poi H., Mangat I., Moe G.W., Hu X., So P.P., et al. Effects of Chronic Gap Junction Conduction-Enhancing Antiarrhythmic Peptide GAP-134 Administration on Experimental Atrial Fibrillation in Dogs. Circ Arrhythm Electrophysiol 2009, 2:171-178.
140. Lazzara R. Amiodarone and Torsade De Pointes. Ann Intern Med 1989, 111:549-551.
141. Ledoux J., Werner M.E., Brayden J.E., Nelson M.T. Calcium-Activated Potassium Channels and the Regulation of Vascular Tone. Physiology (Bethesda ) 2006, 21:69-78.
142. Lee C., Visen N.S., Dhalla N.S., Le H.D., Isaac M., Choptiany P., et al. Inhibitory Profile of SEA0400 [2-[4-[(2,5-Difluorophenyl)Methoxy]Phenoxy]-5-Ethoxyaniline] Assessed on the Cardiac Na+-Ca2+ Exchanger, NCX1.1. J Pharmacol Exp Ther 2004, 311:748-757.
143. Lee K.S. Ibutilide, a New Compound With Potent Class III Antiarrhythmic Activity, Activates a Slow Inward Na+Current in Guinea Pig Ventricular Cells. J Pharmacol Exp Ther 1992, 262:99-108.
144. Lee K.S., Lee E.W. Ionic Mechanism of Ibutilide in Human Atrium: Evidence for a Drug-Induced Na+Current Through a Nifedipine Inhibited Inward Channel. J Pharmacol Exp Ther 1998, 286:9-22.
145. Levy S. Do We Need Pharmacological Therapy for Atrial Fibrillation in the Ablation Era?. J Interv Card Electrophysiol 2006, 17:189-194.
146. Li D., Benardeau A., Nattel S. Contrasting Efficacy of Dofetilide in Differing Experimental Models of Atrial Fibrillation. Circulation 2000, 102:104-112.
147. Li D., Fareh S., Leung T.K., Nattel S. Promotion of Atrial Fibrillation by Heart Failure in Dogs: Atrial Remodeling of a Different Sort. Circulation 1999, 100:87-95.
148. Li D.Q., Feng Y.B., Zhang H.Q. The Relationship Between Gap Junctional Remodeling and Human Atrial Fibrillation. Chin Med J (Engl ) 2004, 117:1256-1258.
149. Li G.R., Sun H.Y., Zhang X.H., Cheng L.C., Chiu S.W., Tse H.F., et al. Omega-3 Polyunsaturated Fatty Acids Inhibit Transient Outward and Ultra-Rapid Delayed Rectifier K+Currents and Na+Current in Human Atrial Myocytes. Cardiovasc Res 2009, 81:286-293.
150. Li N., Timofeyev V., Tuteja D., Xu D., Lu L., Zhang Q., et al. Ablation of a Ca2+-Activated K+Channel (SK2 Channel) Results in Action Potential Prolongation in Atrial Myocytes and Atrial Fibrillation. J Physiol 2009, 587:1087-1100.
151. Linz D.K., Afkham F., Itter G., Rutten H., Wirth K.J. Effect of Atrial Electrical Remodeling on the Efficacy of Antiarrhythmic Drugs: Comparison of Amiodarone With I(Kr)- and I(to)/IKur-Blockade In Vivo Atrial Electrical Remodeling and Antiarrhythmic Drugs. J Cardiovasc Electrophysiol 2007.
152. Liu Y.M., DeFelice L.J., Mazzanti M. Na Channels That Remain Open Throughout the Cardiac Action Potential Plateau. Biophys J 1992, 63:654-662.
153. Lofberg L., Jacobson I., Carlsson L. Electrophysiological and Antiarrhythmic Effects of the Novel Antiarrhythmic Agent AZD7009: a Comparison With Azimilide and AVE0118 in the Acutely Dilated Right Atrium of the Rabbit in Vitro. Europace 2006, 8:549-557.
154. Lombardi F., Terranova P. Pharmacological Treatment of Atrial Fibrillation: Mechanisms of Action and Efficacy of Class III Drugs. Curr Med Chem 2006, 13:1635-1653.
155. Lubitz S.A., Yi B.A., Ellinor P.T. Genetics of Atrial Fibrillation. Cardiol Clin 2009, 27:25-33. vii.
156. Luo C.H., Rudy Y. A Dynamic Model of the Cardiac Ventricular Action Potential. II. Afterdepolarizations, Triggered Activity, and Potentiation. Circ Res 1994, 74:1097-1113.
157. Maltsev V.A., Sabbah H.N., Undrovinas A.I. Late Sodium Current Is a Novel Target for Amiodarone: Studies in Failing Human Myocardium. J Mol Cell Cardiol 2001, 33:923-932.
158. Matsuda T., Ito M., Ishimaru S., Tsuruoka N., Saito T., Iida-Tanaka N., et al. Blockade by NIP-142, an Antiarrhythmic Agent, of Carbachol-Induced Atrial Action Potential Shortening and GIRK1/4 Channel. J Pharmacol Sci 2006, 101:303-310.
159. McNamara R.L., Tamariz L.J., Segal J.B., Bass E.B. Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. Ann Intern Med 2003, 139:1018-1033.
160. Momose Y., Giles W., Szabo G. Acetylcholine-Induced K Current in Amphibian Atrial Cells. Biophys J 1984, 45:20-22.
161. Moorman J.R., Kirsch G.E., Lacerda A.E., Brown A.M. Angiotensin II Modulates Cardiac Na+Channels in Neonatal Rat. Circ Res 1989, 65:1804-1809.
162. Mori K., Hara Y., Saito T., Masuda Y., Nakaya H. Anticholinergic Effects of Class III Antiarrhythmic Drugs in Guinea Pig Atrial Cells. Different Molecular Mechanisms. Circulation 1995, 91:2834-2843.
163. Morillo C.A., Klein G.J., Jones D.L., Guiraudon C.M. Chronic Rapid Atrial Pacing. Structural, Functional, and Electrophysiological Characteristics of a New Model of Sustained Atrial Fibrillation. Circulation 1995, 91:1588-1595.
164. Muller A., Gottwald M., Tudyka T., Linke W., Klaus W., Dhein S. Increase in Gap Junction Conductance by an Antiarrhythmic Peptide. Eur J Pharmacol 1997, 327:65-72.
165. Murphy N.F., Simpson C.R., Jhund P.S., Stewart S., Kirkpatrick M., Chalmers J., et al. A National Survey of the Prevalence, Incidence, Primary Care Burden and Treatment of Atrial Fibrillation in Scotland. Heart 2007, 93:606-612.
166. Murray K.T. Ibutilide. Circulation 1998, 97:493-497.
167. Naccarelli G.V., Wolbrette D.L., Khan M., Bhatta L., Hynes J., Samii S., et al. Old and New Antiarrhythmic Drugs for Converting and Maintaining Sinus Rhythm in Atrial Fibrillation: Comparative Efficacy and Results of Trials. Am J Cardiol 2003, 91:15D-26D.
168. Nakaya H., Furusawa Y., Ogura T., Tamagawa M., Uemura H. Inhibitory Effects of JTV-519, a Novel Cardioprotective Drug, on Potassium Currents and Experimental Atrial Fibrillation in Guinea-Pig Hearts. Br J Pharmacol 2000, 131:1363-1372.
169. Nattel S., Burstein B., Dobrev D. Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications. Circ Arrhythm Electrophysiol 2008, 1:62-73.
170. Nattel S., Khairy P., Roy D., Thibault B., Guerra P., Talajic M., et al. New Approaches to Atrial Fibrillation Management: a Critical Review of a Rapidly Evolving Field. Drugs 2002, 62:2377-2397.
171. Nattel S., Maguy A., Le Bouter S., Yeh Y.H. Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation. Physiol Rev 2007, 87:425-456.
172. Nemeth M., Varro A., Virag L., Hacute, la O., Thormahlen D., Papp J.G. Frequency-Dependent Cardiac Electrophysiologic Effects of Tedisamil: Comparison With Quinidine and Sotalol. J Cardiovasc Pharmacol Ther 1997, 2:273-284.
173. Nerbonne J.M. Molecular Basis of Functional Voltage-Gated K+Channel Diversity in the Mammalian Myocardium. J Physiol 2000, 525(Pt 2):285-298.
174. Ninio D.M., Saint D.A. The Role of Stretch-Activated Channels in Atrial Fibrillation and the Impact of Intracellular Acidosis. Prog Biophys Mol Biol 2008, 97:401-416.
175. Nishida A., Reien Y., Ogura T., Uemura H., Tamagawa M., Yabana H., et al. Effects of Azimilide on the Muscarinic Acetylcholine Receptor-Operated K+Current and Experimental Atrial Fibrillation in Guinea-Pig Hearts. J Pharmacol Sci 2007, 105:229-239.
176. Nishida M., Kurose H. Roles of TRP Channels in the Development of Cardiac Hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 2008, 378:395-406.
177. Noble D., Blaustein M.P. Directionality in Drug Action on Sodium-Calcium Exchange. Ann N Y Acad Sci 2007, 1099:540-543.
178. Ohler A., Ravens U. Effects of E-4031, Almokalant and Tedisamil on Postrest Action Potential Duration of Human Papillary Muscles. J Pharmacol Exp Ther 1994, 270:460-465.
179. Olson T.M., Alekseev A.E., Liu X.K., Park S., Zingman L.V., Bienengraeber M., et al. Kv1.5 Channelopathy Due to KCNA5 Loss-of-Function Mutation Causes Human Atrial Fibrillation. Hum Mol Genet 2006, 15:2185-2191.
180. Opie L.H. Tedisamil in Coronary Disease: Additional Benefits in the Therapy of Atrial Fibrillation?. J Cardiovasc Pharmacol Ther 2003, 8(Suppl 1):S33-S37.
181. Orth P.M., Hesketh J.C., Mak C.K., Yang Y., Lin S., Beatch G.N., et al. RSD1235 Blocks Late I(Na) and Suppresses Early Afterdepolarizations and Torsades De Pointes Induced by Class III Agents. Cardiovasc Res 2006, 70:486-496.
182. Ozgen N., Dun W., Sosunov E.A., Anyukhovsky E.P., Hirose M., Duffy H.S., et al. Early Electrical Remodeling in Rabbit Pulmonary Vein Results From Trafficking of Intracellular SK2 Channels to Membrane Sites. Cardiovasc Res 2007, 75:758-769.
183. Page R.L., Roden D.M. Drug Therapy for Atrial Fibrillation: Where Do We Go From Here?. Nat Rev Drug Discov 2005, 4:899-910.
184. Pandit S.V., Berenfeld O., Anumonwo J.M., Zaritski R.M., Kneller J., Nattel S., et al. Ionic Determinants of Functional Reentry in a 2-D Model of Human Atrial Cells During Simulated Chronic Atrial Fibrillation. Biophys J 2005, 88:3806-3821.
185. Patel C., Yan G.X., Kowey P.R. Dronedarone 74. Circulation 2009, 120:636-644.
186. Persson F., Carlsson L., Duker G., Jacobson I. Blocking Characteristics of HKv1.5 and HKv4.3/HKChIP2.2 After Administration of the Novel Antiarrhythmic Compound AZD7009. J Cardiovasc Pharmacol 2005, 46:7-17.
187. Persson F., Carlsson L., Duker G., Jacobson I. Blocking Characteristics of HERG, HNav1.5, and HKvLQT1/HminK After Administration of the Novel Anti-Arrhythmic Compound AZD7009. J Cardiovasc Electrophysiol 2005, 16:329-341.
188. Peters N.S., Green C.R., Poole-Wilson P.A., Severs N.J. Reduced Content of Connexin43 Gap Junctions in Ventricular Myocardium From Hypertrophied and Ischemic Human Hearts. Circulation 1993, 88:864-875.
189. Pino R., Cerbai E., Calamai G., Alajmo F., Borgioli A., Braconi L., et al. Effect of 5-HT4 Receptor Stimulation on the Pacemaker Current I(f) in Human Isolated Atrial Myocytes. Cardiovasc Res 1998, 40:516-522.
190. Plewan A., Lehmann G., Ndrepepa G., Schreieck J., Alt E.U., Schomig A., et al. Maintenance of Sinus Rhythm After Electrical Cardioversion of Persistent Atrial Fibrillation; Sotalol Vs Bisoprolol. Eur Heart J 2001, 22:1504-1510.
191. Polontchouk L., Haefliger J.A., Ebelt B., Schaefer T., Stuhlmann D., Mehlhorn U., et al. Effects of Chronic Atrial Fibrillation on Gap Junction Distribution in Human and Rat Atria. J Am Coll Cardiol 2001, 38:883-891.
192. Pratt C.M., Reiffel J.A., Ellenbogen K.A., Naccarelli G.V., Kowey P.R. Efficacy and Safety of Prescription Omega-3-Acid Ethyl Esters for the Prevention of Recurrent Symptomatic Atrial Fibrillation: a Prospective Study. Am Heart J 2009, 158:163-169.
193. Pratt C.M., Singh S.N., Al Khalidi H.R., Brum J.M., Holroyde M.J., Marcello S.R., et al. The Efficacy of Azimilide in the Treatment of Atrial Fibrillation in the Presence of Left Ventricular Systolic Dysfunction: Results From the Azimilide Postinfarct Survival Evaluation (ALIVE) Trial. J Am Coll Cardiol 2004, 43:1211-1216.
194. Prystowsky E.N., Freeland S., Branyas N.A., Rardon D.P., Fogel R.I., Padanilam B.J., et al. Clinical Experience With Dofetilide in the Treatment of Patients With Atrial Fibrillation. J Cardiovasc Electrophysiol 2003, 14:S287-S290.
195. Putzke C., Wemhoner K., Sachse F.B., Rinne S., Schlichthorl G., Li X.T., et al. The Acid-Sensitive Potassium Channel TASK-1 in Rat Cardiac Muscle. Cardiovasc Res 2007, 75:59-68.
196. Rahme M.M., Cotter B., Leistad E., Wadhwa M.K., Mohabir R., Ford A.P., et al. Electrophysiological and Antiarrhythmic Effects of the Atrial Selective 5-HT(4) Receptor Antagonist RS-100302 in Experimental Atrial Flutter and Fibrillation. Circulation 1999, 100:2010-2017.
197. Regan C.P., Wallace A.A., Cresswell H.K., Atkins C.L., Lynch J.J. In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-Methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate. J Pharmacol Exp Ther 2006, 316:727-732.
198. Reuter H., Henderson S.A., Han T., Matsuda T., Baba A., Ross R.S., et al. Knockout Mice for Pharmacological Screening: Testing the Specificity of Na+-Ca2+ Exchange Inhibitors. Circ Res 2002, 91:90-92.
199. Rolf S., Haverkamp W., Borggrefe M., Musshoff U., Eckardt L., Mergenthaler J., et al. Effects of Antiarrhythmic Drugs on Cloned Cardiac Voltage-Gated Potassium Channels Expressed in Xenopus Oocytes. Naunyn Schmiedebergs Arch Pharmacol 2000, 362:22-31.
200. Rossman E.I., Liu K., Morgan G.A., Swillo R.E., Krueger J.A., Gardell S.J., et al. The Gap Junction Modifier, GAP-134 [(2S, 4R)-1-(2-Aminoacetyl)-4-Benzamido-Pyrrolidine-2-Carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model. J Pharmacol Exp Ther 2009, 329:1127-1133.
201. Roy D., Pratt C.M., Torp-Pedersen C., Wyse D.G., Toft E., Juul-Moller S., et al. Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: a Phase 3, Randomized, Placebo-Controlled Trial. Circulation 2008, 117:1518-1525.
202. Sakabe M., Fujiki A., Nishida K., Sugao M., Nagasawa H., Tsuneda T., et al. Enalapril Preserves Sinus Node Function in a Canine Atrial Fibrillation Model Induced by Rapid Atrial Pacing. J Cardiovasc Electrophysiol 2005, 16:1209-1214.
203. Sanguinetti M.C., Tristani-Firouzi M. HERG Potassium Channels and Cardiac Arrhythmia. Nature 2006, 440:463-469.
204. Savelieva I., Camm J. Is There Any Hope for Angiotensin-Converting Enzyme Inhibitors in Atrial Fibrillation?. Am Heart J 2007, 154:403-406.
205. Savelieva I., Camm J. Statins and Polyunsaturated Fatty Acids for Treatment of Atrial Fibrillation. Nat Clin Pract Cardiovasc Med 2008, 5:30-41.
206. Savelieva I., Kourliouros A., Camm J. Primary and Secondary Prevention of Atrial Fibrillation With Statins and Polyunsaturated Fatty Acids: Review of Evidence and Clinical Relevance. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:207-219.
207. 2+-Exchange. Cardiovasc Res 2007, 73:37-47.
208. Schram G., Zhang L., Derakhchan K., Ehrlich J.R., Belardinelli L., Nattel S. Ranolazine: Ion-Channel-Blocking Actions and in Vivo Electrophysiological Effects. Br J Pharmacol 2004, 142:1300-1308.
209. Schwartzman D., Harvey M.N., Hoyt R.H., Koehler J.L., Ujhelyi M.R., Euler D.E. Utility of Adjunctive Single Oral Bolus Propafenone Therapy in Patients With Atrial Defibrillators. Europace 2006, 8:211-215.
210. Scirica B.M., Morrow D.A., Hod H., Murphy S.A., Belardinelli L., Hedgepeth C.M., et al. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non ST-Segment Elevation Acute Coronary Syndrome: Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation 2007, 116:1647-1652.
211. Severs N.J., Bruce A.F., Dupont E., Rothery S. Remodelling of Gap Junctions and Connexin Expression in Diseased Myocardium. Cardiovasc Res 2008, 80:9-19.
212. Shiroshita-Takeshita A., Sakabe M., Haugan K., Hennan J.K., Nattel S. Model-Dependent Effects of the Gap Junction Conduction-Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs. Circulation 2007, 115:310-318.
213. Shryock J.C., Belardinelli L. Inhibition of Late Sodium Current to Reduce Electrical and Mechanical Dysfunction of Ischaemic Myocardium. Br J Pharmacol 2008, 153:1128-1132.
214. Singh B.N., Vaughan Williams E.M. The Effect of Amiodarone, a New Anti-Anginal Drug, on Cardiac Muscle. Br J Pharmacol 1970, 39:657-667.
215. Singh S., Zoble R.G., Yellen L., Brodsky M.A., Feld G.K., Berk M., et al. Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study. Circulation 2000, 102:2385-2390.
216. Sipido K.R., Varro A., Eisner D. Sodium Calcium Exchange As a Target for Antiarrhythmic Therapy. Handb Exp Pharmacol 2006, 159-199.
217. Sood S., Chelu M.G., van Oort R.J., Skapura D., Santonastasi M., Dobrev D., et al. Intracellular Calcium Leak Due to FKBP12.6 Deficiency in Mice Facilitates the Inducibility of Atrial Fibrillation. Heart Rhythm 2008, 5:1047-1054.
218. Sridhar A., da Cunha D.N., Lacombe V.A., Zhou Q., Fox J.J., Hamlin R.L., et al. The Plateau Outward Current in Canine Ventricle, Sensitive to 4-Aminopyridine, Is a Constitutive Contributor to Ventricular Repolarization. Br J Pharmacol 2007, 152:870-879.
219. Stambler B.S., Wood M.A., Ellenbogen K.A., Perry K.T., Wakefield L.K., Vanderlugt J.T. Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996, 94:1613-1621.
220. Starmer C.F., Grant A.O., Strauss H.C. Mechanisms of Use-Dependent Block of Sodium Channels in Excitable Membranes by Local Anesthetics. Biophys J 1984, 46:15-27.
221. Stump G.L., Wallace A.A., Regan C.P., Lynch J.J. In Vivo Antiarrhythmic and Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker (2-Isopropyl-5-Methylcyclohexyl) Diphenylphosphine Oxide. J Pharmacol Exp Ther 2005, 315:1362-1367.
222. Sun W., Sarma J.S., Singh B.N. Electrophysiological Effects of Dronedarone (SR33589), a Noniodinated Benzofuran Derivative, in the Rabbit Heart: Comparison With Amiodarone. Circulation 1999, 100:2276-2281.
223. Sun W., Sarma J.S., Singh B.N. Chronic and Acute Effects of Dronedarone on the Action Potential of Rabbit Atrial Muscle Preparations: Comparison With Amiodarone. J Cardiovasc Pharmacol 2002, 39:677-684.
224. Takahashi K., Takahashi T., Suzuki T., Onishi M., Tanaka Y., Hamano-Takahashi A., et al. Protective Effects of SEA0400, a Novel and Selective Inhibitor of the Na+/Ca2+ Exchanger, on Myocardial Ischemia-Reperfusion Injuries. Eur J Pharmacol 2003, 458:155-162.
225. Tamargo J., Caballero R., Delpon E. Pharmacological Approaches in the Treatment of Atrial Fibrillation. Curr Med Chem 2004, 11:13-28.
226. Tamargo J., Caballero R., Gomez R., Valenzuela C., Delpon E. Pharmacology of Cardiac Potassium Channels. Cardiovasc Res 2004, 62:9-33.
227. Tanaka H., Hashimoto N. A Multiple Ion Channel Blocker, NIP-142, for the Treatment of Atrial Fibrillation. Cardiovasc Drug Rev 2007, 25:342-356.
228. Tande P.M., Bjornstad H., Yang T., Refsum H. Rate-Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK-68, 798: Potent in Guinea Pig but No Effect in Rat Myocardium. J Cardiovasc Pharmacol 1990, 16:401-410.
229. Tse H.F., Lau C.P. Electrophysiologic Actions of Dl-Sotalol in Patients With Persistent Atrial Fibrillation. J Am Coll Cardiol 2002, 40:2150-2155.
230. Tselentakis E.V., Woodford E., Chandy J., Gaudette G.R., Saltman A.E. Inflammation Effects on the Electrical Properties of Atrial Tissue and Inducibility of Postoperative Atrial Fibrillation. J Surg Res 2006, 135:68-75.
231. van der Velden H.M., Ausma J., Rook M.B., Hellemons A.J., van Veen T.A., Allessie M.A., et al. Gap Junctional Remodeling in Relation to Stabilization of Atrial Fibrillation in the Goat. Cardiovasc Res 2000, 46:476-486.
232. Van Gelder I.C., Groenveld H.F., Crijns H.J., Tuininga Y.S., Tijssen J.G., Alings A.M., et al. Lenient Versus Strict Rate Control in Patients With Atrial Fibrillation. N Engl J Med 2010, 362:1363-1373.
233. Van Wagoner D.R. Evaluating the Impact of Atrial Dilatation on Atrial Calcium Cycling. Eur Heart J 2008, 29:1084-1085.
234. Van Wagoner D.R. Oxidative Stress and Inflammation in Atrial Fibrillation: Role in Pathogenesis and Potential As a Therapeutic Target. J Cardiovasc Pharmacol 2008, 52:306-313.
235. + Current Densities and Kv1.5 Expression Are Reduced in Chronic Human Atrial Fibrillation. Circ Res 1997, 80:772-781.
236. Van Wagoner D.R., Voigt N., Bunnell B., Barnard J., Schotten U., Nattel S., et al. Transient Receptor Potential Canonical (TRPC) Channel Subunit Remodeling in Clinical and Experimental AF. Heart Rhythm Abstract 2009, PO06-PO77.
237. Vaquero M., Calvo D., Jalife J. Cardiac Fibrillation: From Ion Channels to Rotors in the Human Heart. Heart Rhythm 2008, 5:872-879.
238. Varro A., Takacs J., Nemeth M., Hala O., Virag L., Iost N., et al. Electrophysiological Effects of Dronedarone (SR 33589), a Noniodinated Amiodarone Derivative in the Canine Heart: Comparison With Amiodarone. Br J Pharmacol 2001, 133:625-634.
239. Vassort G., Alvarez J. Transient Receptor Potential: a Large Family of New Channels of Which Several Are Involved in Cardiac Arrhythmia. Can J Physiol Pharmacol 2009, 87:100-107.
240. Vaughan Williams E.M. Classification of Antidysrhythmic Drugs. Pharmacol Ther B 1975, 1:115-138.
241. Vest J.A., Wehrens X.H., Reiken S.R., Lehnart S.E., Dobrev D., Chandra P., et al. Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation. Circulation 2005, 111:2025-2032.
242. Voigt N., Friedrich A., Bock M., Wettwer E., Christ T., Knaut M., et al. Differential Phosphorylation-Dependent Regulation of Constitutively Active and Muscarinic Receptor-Activated IK, ACh Channels in Patients With Chronic Atrial Fibrillation. Cardiovasc Res 2007, 74:426-437.
243. Voigt N., Maguy A., Yeh Y.H., Qi X., Ravens U., Dobrev D., et al. Changes in I K, ACh Single-Channel Activity With Atrial Tachycardia Remodelling in Canine Atrial Cardiomyocytes. Cardiovasc Res 2008, 77:35-43.
244. Voigt N., Rozmaritsa N., Trausch A., Zimniak T., Christ T., Wettwer E., et al. Inhibition of IK, ACh Current May Contribute to Clinical Efficacy of Class I and Class III Antiarrhythmic Drugs in Patients With Atrial Fibrillation. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:251-259.
245. von Lewinski D., Kockskamper J., Rubertus S.U., Zhu D., Schmitto J.D., Schondube F.A., et al. Direct Pro-Arrhythmogenic Effects of Angiotensin II Can Be Suppressed by AT1 Receptor Blockade in Human Atrial Myocardium. Eur J Heart Fail 2008, 10:1172-1176.
246. Vos M.A., Golitsyn S.R., Stangl K., Ruda M.Y., Van Wijk L.V., Harry J.D., et al. Superiority of Ibutilide (a New Class III Agent) Over DL-Sotalol in Converting Atrial Flutter and Atrial Fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998, 79:568-575.
247. Wang Z., Fermini B., Nattel S. Effects of Flecainide, Quinidine, and 4-Aminopyridine on Transient Outward and Ultrarapid Delayed Rectifier Currents in Human Atrial Myocytes. J Pharmacol Exp Ther 1995, 272:184-196.
248. Watanabe H., Murakami M., Ohba T., Ono K., Ito H. The Pathological Role of Transient Receptor Potential Channels in Heart Disease. Circ J 2009, 73:419-427.
249. Watano T., Kimura J., Morita T., Nakanishi H. A Novel Antagonist, No. 7943, of the Na+/Ca2+ Exchange Current in Guinea-Pig Cardiac Ventricular Cells. Br J Pharmacol 1996, 119:555-563.
250. Wettwer E., Hala O., Christ T., Heubach J.F., Dobrev D., Knaut M., et al. Role of IKur in Controlling Action Potential Shape and Contractility in the Human Atrium: Influence of Chronic Atrial Fibrillation. Circulation 2004, 110:2299-2306.
251. Wettwer E., Himmel H.M., Amos G.J., Li Q., Metzger F., Ravens U. Mechanism of Block by Tedisamil of Transient Outward Current in Human Ventricular Subepicardial Myocytes. Br J Pharmacol 1998, 125:659-666.
252. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial Fibrillation Begets Atrial Fibrillation. A Study in Awake Chronically Instrumented Goats. Circulation 1995, 92:1954-1968.
253. Wirth K.J., Brendel J., Steinmeyer K., Linz D.K., Rutten H., Gogelein H. In Vitro and in Vivo Effects of the Atrial Selective Antiarrhythmic Compound AVE1231 1. J Cardiovasc Pharmacol 2007, 49:197-206.
254. Wit A.L., Duffy H.S. Drug Development for Treatment of Cardiac Arrhythmias: Targeting the Gap Junctions. Am J Physiol Heart Circ Physiol 2008, 294:H16-H18.
255. Wongcharoen W., Chen Y.C., Chen Y.J., Chang C.M., Yeh H.I., Lin C.I., et al. Effects of a Na+/Ca2+ Exchanger Inhibitor on Pulmonary Vein Electrical Activity and Ouabain-Induced Arrhythmogenicity. Cardiovasc Res 2006, 70:497-508.
256. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., et al. A Comparison of Rate Control and Rhythm Control in Patients With Atrial Fibrillation. N Engl J Med 2002, 347:1825-1833.
257. Xiao Y.F., Sigg D.C., Leaf A. The Antiarrhythmic Effect of N-3 Polyunsaturated Fatty Acids: Modulation of Cardiac Ion Channels As a Potential Mechanism. J Membr Biol 2005, 206:141-154.
258. Xu Y., Tuteja D., Zhang Z., Xu D., Zhang Y., Rodriguez J., et al. Molecular Identification and Functional Roles of a Ca(2+)-Activated K+Channel in Human and Mouse Hearts. J Biol Chem 2003, 278:49085-49094.
259. Yang T., Snyders D.J., Roden D.M. Ibutilide, a Methanesulfonanilide Antiarrhythmic, Is a Potent Blocker of the Rapidly Activating Delayed Rectifier K+Current (IKr) in AT-1 Cells. Concentration-, Time-, Voltage-, and Use-Dependent Effects. Circulation 1995, 91:1799-1806.